These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. de Oliveira Dias JR; de Andrade GC; Kniggendorf VF; Novais EA; Maia A; Meyer C; Watanabe SES; Farah ME; Rodrigues EB Retina; 2017 Aug; 37(8):1499-1507. PubMed ID: 27798520 [TBL] [Abstract][Full Text] [Related]
5. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol. Jørstad ØK; Faber RT; Moe MC Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485 [TBL] [Abstract][Full Text] [Related]
6. Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age-related macular degeneration. Sawada T; Wang X; Sawada O; Saishin Y; Ohji M Clin Exp Ophthalmol; 2018 Jan; 46(1):46-53. PubMed ID: 28621038 [TBL] [Abstract][Full Text] [Related]
7. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration. Yun C; Oh J; Ahn J; Hwang SY; Lee B; Kim SW; Huh K Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1693-702. PubMed ID: 26781585 [TBL] [Abstract][Full Text] [Related]
11. SHORT-TERM SAFETY OF 2 MG INTRAVITREAL ZIV-AFLIBERCEPT. Chhablani J; Dedhia CJ; Peguda HK; Stewart M Retina; 2017 Oct; 37(10):1859-1865. PubMed ID: 28060148 [TBL] [Abstract][Full Text] [Related]
12. [Visual and anatomical outcomes of three intravitreal aflibercept injections in eyes with neovascular form of age-related macular degeneration]. Kałuiny JJ; Majer A; Jaworowska-Cieślińska I Klin Oczna; 2015; 117(1):9-13. PubMed ID: 26349151 [TBL] [Abstract][Full Text] [Related]
13. Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD. Batioglu F; Demirel S; Özmert E; Abdullayev A; Bilici S BMC Ophthalmol; 2015 Apr; 15():40. PubMed ID: 25885684 [TBL] [Abstract][Full Text] [Related]
14. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Cho H; Shah CP; Weber M; Heier JS Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration. Saito M; Kano M; Itagaki K; Sekiryu T Jpn J Ophthalmol; 2017 Jan; 61(1):74-83. PubMed ID: 27660164 [TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of ziv-aflibercept in retinal diseases. Mansour AM; Ashraf M; Dedhia CJ; Charbaji A; Souka AAR; Chhablani J Br J Ophthalmol; 2017 Oct; 101(10):1374-1376. PubMed ID: 28270485 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration. Matsumoto H; Hiroe T; Morimoto M; Mimura K; Ito A; Akiyama H Jpn J Ophthalmol; 2018 Mar; 62(2):144-150. PubMed ID: 29411171 [TBL] [Abstract][Full Text] [Related]
20. FLATTENING OF A TREATMENT-RESISTANT RETINAL PIGMENT EPITHELIAL DETACHMENT AFTER A SINGLE INTRAVITREAL INJECTION OF ZIV-AFLIBERCEPT. Yogi R; Stewart M; Chhablani J Retin Cases Brief Rep; 2017 Spring; 11(2):111-113. PubMed ID: 27078613 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]